bladder cancer

Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes
Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes
Fierce Pharma
Astellas
Seattle Genetics
Padcev
advanced bladder cancer
bladder cancer
Flag link:
Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response
Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response
Reuters
Seattle Genetics
Astellas
bladder cancer
Padcev
Flag link:
Roche's Tecentriq fails trial in form of urothelial cancer
Roche's Tecentriq fails trial in form of urothelial cancer
Reuters
Roche
Genentech
clinical trials
Tecentriq
urothelial cancer
bladder cancer
Flag link:
Merck's Blockbuster Drug Wins Key New FDA Approval
Merck's Blockbuster Drug Wins Key New FDA Approval
Motley Fool
Merck
Keytruda
bladder cancer
NMIBC
Flag link:
Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores
Merck KGaA, Pfizer's Bavencio set to seal bladder cancer approval after confirmatory trial scores
Endpoints
Merck KGaA
Pfizer
Bavencio
bladder cancer
FDA
Flag link:
Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK
Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK
Fierce Pharma
Merck
Keytruda
FDA
bladder cancer
NMIBC
Flag link:
FerGene’s Bladder Cancer Phase III Trial Hits Its Mark
FerGene’s Bladder Cancer Phase III Trial Hits Its Mark
BioSpace
FerGene
gene therapy
bladder cancer
NMIBC
Ferring Pharmaceuticals
Blackstone Life Sciences
clinical trials
Flag link:
Merck’s Keytruda gets FDA priority review for high-risk NMIBC
Merck’s Keytruda gets FDA priority review for high-risk NMIBC
Pharmaceutical Business Review
Merck
Keytruda
bladder cancer
priority review
NMIBC
FDA
Flag link:
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
ESMO: Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers
Fierce Biotech
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
ESMO
urothelial cancer
Flag link:
Oncologists listen when the FDA speaks, even after a drug hits the market
Oncologists listen when the FDA speaks, even after a drug hits the market
Endpoints
FDA
oncology
oncologists
drug approvals
bladder cancer
Flag link:
Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer
Sesen Bio reports data update from phase 3 trial for high-risk non-muscle invasive bladder cancer
Pharmaceutical Business Review
Sesen Bio
clinical trials
Vicinium
bladder cancer
Flag link:
Roche says test showed Tecentriq helped vs bladder cancer
Roche says test showed Tecentriq helped vs bladder cancer
Reuters
Roche
Tecentriq
bladder cancer
Flag link:
Did cancer clinical trials stay on track at ASCO 2019?
Did cancer clinical trials stay on track at ASCO 2019?
Pharmaforum
ASCO
clinical trials
cancer
ASCO 2019
bladder cancer
breast cancer
prostate cancer
pancreatic cancer
Flag link:
Inovio axes staffers, cancer program to 'sharpen focus,' save cash
Inovio axes staffers, cancer program to 'sharpen focus,' save cash
Fierce Biotech
Inovio
layoffs
bladder cancer
diagnostics
Flag link:
Cold virus strain could be used as therapy for bladder cancer – study
Cold virus strain could be used as therapy for bladder cancer – study
Pharmaforum
bladder cancer
coxsackievirus virus
Flag link:
Roche throws in the towel on Tecentriq bladder, myeloma trials
Roche throws in the towel on Tecentriq bladder, myeloma trials
Fierce Pharma
Roche
Tecentriq
bladder cancer
Multiple Myeloma
clinical trials
Flag link:
Clovis down after discontinuing rucaparib bladder cancer trial
Clovis down after discontinuing rucaparib bladder cancer trial
BioCentury
Clovis Oncology
Rubraca
bladder cancer
Flag link:
J&J's Balversa gets accelerated approval for bladder cancer
J&J's Balversa gets accelerated approval for bladder cancer
BioCentury
JNJ
Janssen
Balversa
bladder cancer
FDA
Flag link:
NanOlogy enrolls first patient in phase 1/2 clinical trial of NanoDoce to treat bladder cancer
NanOlogy enrolls first patient in phase 1/2 clinical trial of NanoDoce to treat bladder cancer
Pharmaceutical Business Review
NanOlogy
bladder cancer
NanoDoce
clinical trials
Flag link:
Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody
Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody
Endpoints
Seattle Genetics
Astellas
enfortumab vedotin
bladder cancer
Flag link:

Pages